INTRODUCTION: The Y-box binding protein-1 (YB-1) is a multifunctional oncoprotein involved in the proliferation and aggressiveness of cancer cells. The aim of this study was to determine whether strong YB-1 expression in neoplastic cells of colorectal liver metastases (CRLM) may have an impact on liver disease-free survival following liver resection. MATERIALS AND METHODS: Immunohistochemistry was performed to evaluate YB-1 in 66 patients who underwent liver resection for CRLM. YB-1 expression was classified as weak (low-staining intensity) and strong (high-staining intensity). RESULTS: YB-1 expression was observed in the cytoplasm of all CRLM. YB-1 expression was weak in 17 patients (25.8%) and strong in 49 patients (74.2%). Liver recurrence rate was significantly higher in the strong than in the weak expression group: 55.1 vs. 23.5% (p = 0.023). Multivariable logistic regression analysis showed that YB-1 strong expression was the only independent risk factor for liver recurrence. The 5-year specific liver disease-free survival rate was 76.0% in the weak expression group and 41.5% in the strong expression group (p = 0.034). These results were not influenced by clinical prognostic factors of tumor recurrence. CONCLUSIONS: This is the first study showing that the degree of YB-1 expression in tissue specimens of CRLM predicts liver recurrence following liver resection.
INTRODUCTION: The Y-box binding protein-1 (YB-1) is a multifunctional oncoprotein involved in the proliferation and aggressiveness of cancer cells. The aim of this study was to determine whether strong YB-1 expression in neoplastic cells of colorectal liver metastases (CRLM) may have an impact on liver disease-free survival following liver resection. MATERIALS AND METHODS: Immunohistochemistry was performed to evaluate YB-1 in 66 patients who underwent liver resection for CRLM. YB-1 expression was classified as weak (low-staining intensity) and strong (high-staining intensity). RESULTS:YB-1 expression was observed in the cytoplasm of all CRLM. YB-1 expression was weak in 17 patients (25.8%) and strong in 49 patients (74.2%). Liver recurrence rate was significantly higher in the strong than in the weak expression group: 55.1 vs. 23.5% (p = 0.023). Multivariable logistic regression analysis showed that YB-1 strong expression was the only independent risk factor for liver recurrence. The 5-year specific liver disease-free survival rate was 76.0% in the weak expression group and 41.5% in the strong expression group (p = 0.034). These results were not influenced by clinical prognostic factors of tumor recurrence. CONCLUSIONS: This is the first study showing that the degree of YB-1 expression in tissue specimens of CRLM predicts liver recurrence following liver resection.
Authors: Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru Journal: Ann Surg Date: 2013-10 Impact factor: 12.969
Authors: Michael G House; Hiromichi Ito; Mithat Gönen; Yuman Fong; Peter J Allen; Ronald P DeMatteo; Murray F Brennan; Leslie H Blumgart; William R Jarnagin; Michael I D'Angelica Journal: J Am Coll Surg Date: 2010-05 Impact factor: 6.113
Authors: Eric Van Cutsem; Bernard Nordlinger; Rene Adam; Claus-Henning Köhne; Carmelo Pozzo; Graeme Poston; Marc Ychou; Philippe Rougier Journal: Eur J Cancer Date: 2006-08-10 Impact factor: 9.162
Authors: S Iwatsuki; I Dvorchik; J R Madariaga; J W Marsh; F Dodson; A C Bonham; D A Geller; T J Gayowski; J J Fung; T E Starzl Journal: J Am Coll Surg Date: 1999-09 Impact factor: 6.113
Authors: C Gessner; C Woischwill; A Schumacher; U Liebers; H Kuhn; P Stiehl; K Jürchott; H D Royer; C Witt; G Wolff Journal: Eur Respir J Date: 2004-01 Impact factor: 16.671
Authors: Georgios Karagkounis; Michael S Torbenson; Hubert D Daniel; Nilofer S Azad; Luis A Diaz; Ross C Donehower; Kenzo Hirose; Nita Ahuja; Timothy M Pawlik; Michael A Choti Journal: Cancer Date: 2013-09-19 Impact factor: 6.860